Trial reportClinical oral investigations2026
Anhydrous stannous fluoride toothpaste in dentin hypersensitivity: clinician-assessed and patient-reported outcomes from two controlled trials.
Trial report in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo confirm anti-sensitivity efficacy of a new anhydrous 0.454% stannous fluoride (SnF MATERIALS AND
methodsTwo independent, examiner-blind, parallel studies enrolled healthy adults with dentin hypersensitivity (DH). Participants were randomized to brush twice-daily with either the SnF₂ toothpaste (Test) or a standard fluoride toothpaste (Reference). DH was assessed by clinician via evaporative (Schiff scale) and tactile (Yeaple probe) stimuli. Participant-reported outcomes were measured using the Labelled Magnitude Scales (LMS) (for DH pain), and the DH Experience Questionnaire (DHEQ-48) (for impact on oral health-related quality-of-life).
results104 participants in Study 1 and 113 participants in Study 2 (18-65 years) were randomized. In both studies, the Test treatment showed a statistically significant decrease in Schiff sensitivity scores, an increase in tactile threshold, and an improvement in LMS domain scores from baseline to Day 28 and 56. The improvements in all three measures were greater than those observed for the Reference treatment (all, p < 0.05). Additionally, Study 1 showed significantly greater improvements in DHEQ scores in the Test treatment versus the Reference at Day 56. Toothpastes were generally well-tolerated.
conclusionsTwice-daily use of the 0.454% SnF₂ toothpaste significantly and progressively reduced examiner-assessed and perceived DH over 56 days versus standard fluoride toothpaste. CLINICAL RELEVANCE: The studies confirm the efficacy of the novel 0.454% SnF₂ toothpaste in delivering meaningful relief from DH, supporting its role as a patient-centred treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.